About InVitria
InVitria is a company based in Fort Collins (United States) founded in 2006. It operates as a B2B. InVitria offers products and services including Cellastim S, Exbumin, Optibumin 20, Optibumin 25, and Optiferrin. InVitria operates in a competitive market with competitors including Abcam, Stem Cell Technologies, Aldevron, Blaze Bioscience and Teknova, among others.
- Headquarter Fort Collins, United States
- SectorsHealthcare
- Phone•••• ••••
- Website invitria.com
- Social X Facebook
Products & Services of InVitria
InVitria offers a comprehensive portfolio of products and services, including Cellastim S, Exbumin, Optibumin 20, Optibumin 25, and Optiferrin.
Recombinant human albumin for cell culture media applications.
Recombinant human albumin excipient for formulation purposes.
Recombinant human albumin for biomanufacturing processes.
Recombinant human albumin used in cell culture supplements.
Recombinant human transferrin for blood-free media.
People of InVitria
8 people are tracked at InVitria (6 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Vladimir Akoyev | VP, Analytical Development & Manufacturing Sciences | Leadership |
L. Mark Lagrimini | VP, Upstream Product Development | Leadership |
Scott E. Deeter | President | Leadership |
Ron Backman | VP, Quality | Leadership |
Andrew Simon | Director, Molecular Biology | Leadership |
Jacob Weber | Ph.d., Director, Process Development | Leadership |
Rupesh Shrestha | Process Development Scientist | Team |
Jake Hanks | Business Development Manager | Team |
Complete people profiles for InVitria
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of InVitria
InVitria operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, Aldevron, Blaze Bioscience and Teknova, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| aldevron.com | 1998 | Fargo, United States | – | 747 | Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications | |
| blazebioscience.com | 2010 | Seattle, United States | $123.7M | 27 | Blaze Bioscience is focused on improving cancer patient outcomes. | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| bbisolutions.com | 1986 | Crumlin, United Kingdom | – | 301 | Kits and reagents are developed for life science research applications. | |
| sigmaaldrich.com | 1951 | St. Louis, United States | – | 4,709 | Biochemical and organic chemicals are developed for scientific research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. |
Detailed competitors of InVitria
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InVitria
Websites that share an audience with InVitria (invitria.com).
Websites whose visitors overlap most with InVitria. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellntec.com | 100% | 2.8K | #6,513,861 | View details | |
| glycosan.com | 96% | – | – | View details | |
| vitrolife.com | 83% | 25.7K | #1,076,866 | View details | |
| cyagen.com | 80% | 36.4K | #932,590 | View details | |
| irvinesci.com | 76% | 6.6K | #3,329,806 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for InVitria
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Invitria
Complete news archive for InVitria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to InVitria
10 companies that operate in the same segment as InVitria (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InVitria
InVitria was founded in 2006.
InVitria is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
InVitria produces recombinant, animal-free cell culture media and supplements for applications in gene therapy, cell therapy, vaccine production, and food science. They operate from Junction City, Kansas, USA, offering scalable products without blood-derived components. Their solutions support clinical programs worldwide by providing high-performing, chemically defined options for biologics manufacturing, incorporated in various therapeutics.
InVitria's top competitors include Abcam, Meridian Bioscience and Aldevron.
InVitria offers Cellastim S, Exbumin, Optibumin 20, Optibumin 25, and Optiferrin.